DDInter256 DDInter899
Butabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates.[A201977,L13613] This makes butabarbital a useful drug for treating severe insomnia and pre-operative anxiety.[A201977,L13613] Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines. Its short duration of action gives butabarbital a high abuse potential, comparable to [secobarbital].[A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Butabarbital {u} (Compound) resembles {v} (Compound) Butalbital
Butabarbital {u} (Compound) resembles {v} (Compound) Pentobarbital
Butabarbital {u} (Compound) binds {v} (Gene) GABRB2
Butabarbital {u} (Compound) causes {v} (Side Effect) Dermatitis exfoliative
Butabarbital (Compound) resembles Butalbital (Compound)
Butabarbital (Compound) resembles Pentobarbital (Compound)
Butabarbital (Compound) binds GABRB2 (Gene)
Butabarbital (Compound) causes Dermatitis exfoliative (Side Effect)